Drug survival for biologics in psoriasis patients: real world evidence for Greece during the period 2016-2020.
Elizabeth LazaridouGeorgia KourlabaStylianos RavanidisGeorge GounelasGaryfallia StefanouAnastasios TsolakidisKonstantinos MathioudakisZoe ApallaPublished in: Clinical and experimental dermatology (2024)
Our findings confirm previous reports regarding the importance of efficient 1st line biologics and the vulnerability of patients to co-existent PsA. The utilitzation of antibodies against interleukins confer to high drug survival rates. These results will assist clinical management of psoriasis patients in Greece.